Fig. 2: High-expression of RBM15 is associated with poor outcomes of HCC. | Cell Death Discovery

Fig. 2: High-expression of RBM15 is associated with poor outcomes of HCC.

From: RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner

Fig. 2: High-expression of RBM15 is associated with poor outcomes of HCC.The alternative text for this image may have been generated using AI.

a–c The expression of RBM15 mRNA was compared between tumors and normal tissues based on GEO datasets (GSE14520, GSE62232, and GSE6764; **p < 0.01, ****p < 0.0001; t test); d the expression of RBM15 protein was analyzed in ten pairs of HCC tissue (T: tumor; A: adjacent tissue); e representative IHC images of RBM15 staining in tumor and adjacent tissues of cohort-1 patients (scale bar, 100 μm; magnifications, ×100 and ×200); f IHC scores of matched tumors and adjacent tissues of cohort-1 were calculated based on RBM15 staining (****p < 0.0001; t test); g Kaplan–Meier analysis of overall survival of cohort-1 patients based on RBM15 expression; h Kaplan–Meier analysis of disease-free survival of cohort-1 patients based on RBM15 expression; i nomogram to predict 3- and 5-year overall survival. Each risk factor corresponded to a point by drawing a line straight upward to the points axis. The sum of the points located on the total points axis showed the probability of overall survival by drawing a line straight down to the survival axis. j The time-dependent ROC curves comparing the RBM15 model with the TNM model based on the training group (cohort-2); k the time-dependent ROC curves comparing the RBM15 model with the TNM model based on the validation group (cohort-1). The data are presented as mean ± SD.

Back to article page